Testing nivolumab plus entinostat for high-risk childhood cancers
Part of Brain & nervous system, Cancer clinical trials.
This trial studies whether nivolumab (an immune therapy) plus entinostat (an epigenetic medicine) can help children and teens with high-risk cancers that have come back, worsened, or did not respond to prior treatment. It also looks at specific tumor “biomarkers” to group patients and guide how the study is run.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a child or teen age 2 to 21 with a high-risk cancer that is relapsed, refractory, or progressing, or newly diagnosed high-grade brain tumor in a specific genetic condition.
- Your cancer type fits the study list (for example certain brain tumors, neuroblastoma, kidney cancer, rhabdoid tumors, or certain soft-tissue/bone cancers).
- Your doctors must find specific tumor biomarkers using approved tumor testing (like sequencing and/or special lab staining).
- Your latest tumor scan must show measurable disease, and you should be generally well enough for treatment.
- Your blood and organ tests must meet limits (blood counts, liver tests, kidney tests), and your heart rhythm test (ECG) must be acceptable.
- You must be able to swallow the study pills and avoid certain recent medicines or procedures that would interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug (entrectinib) in very young children (under 3) with a newly diagnosed brain tumor that has a specific genetic change (NTRK or ROS1 fusion). The drug works by blocking signals that help the tumor grow, and is given as the first treatment, before any chemotherapy or radiation.
This trial tests a new immunotherapy drug (nivolumab) in children and adults with certain hard-to-treat solid tumors. It may help if standard treatments haven't worked or aren't an option.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This Phase 2 trial studies a targeted treatment approach for children and young adults with advanced neuroblastoma (a childhood cancer). It may help by using lab-tested cancer features to guide therapy after initial treatment and transplant.
Hear when a new CNS Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.